Hypercholesterolemia induced by cholesterol- or cystine-enriched diets is characterized by different plasma lipoprotein and apolipoprotein concentrations in rats.
This study examined the effects of diet-induced hypercholesterolemia on plasma apolipoprotein (apo) concentrations and hepatic apolipoprotein mRNA levels in rats. Hypercholesterolemia was induced by feeding rats diets containing an excess of either cholesterol or cystine. After cholesterol feeding, plasma apo E and apo B concentrations were lower (-65%, P < 0.001) and greater (+39%, P < 0.01), respectively, compared with control diet-fed rats. After cystine feeding, plasma apo B and apo E concentrations were greater (+46%, P < 0.01 and +75%, P < 0.001, respectively) and plasma apo A-IV concentration was lower (-29%, P < 0.001) than in rats fed control diet. After cholesterol or cystine feeding, a tendency (one-way ANOVA, P = 0.08) for greater apo B mRNA level (+42% and +47%, respectively) was observed compared with control diet-fed rats. No difference emerged between groups for apo E and apo A-I mRNA levels. An opposite effect of cholesterol and cystine feeding was shown for apo A-IV mRNA level, i.e., higher after cholesterol feeding (+47%, P < 0.05) and lower after cystine feeding (-65%, P < 0.01). From this work, it seems that hypercholesterolemia induced by dietary cholesterol or by increased cholesterogenesis in cystine-fed rats is characterized by different plasma lipoprotein and apolipoprotein concentrations and is associated with different apolipoprotein gene expression in the liver.
Sérougne
C
C
Laboratoire de Physiologie de la Nutrition, Université Paris Sud, Orsay, France.
Felgines
C
C
Férézou
J
J
Hajri
T
T
Bertin
C
C
Mazur
A
A
D000199:Actins / Q000032:analysis / Q000235:genetics; D000818:Animals; D001053:Apolipoproteins / Q000032:analysis* / Q000097:blood / Q000235:genetics; D001057:Apolipoproteins E / Q000097:blood; D002784:Cholesterol / Q000032:analysis / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage* / Q000009:adverse effects; D003553:Cystine / Q000008:administration & dosage* / Q000009:adverse effects; D006903:Hydroxymethylglutaryl CoA Reductases / Q000378:metabolism; D006937:Hypercholesterolemia / Q000097:blood / Q000209:etiology / Q000378:metabolism*; D008074:Lipoproteins / Q000097:blood*; D008099:Liver / Q000737:chemistry / Q000201:enzymology; D008297:Male; D012333:RNA, Messenger / Q000032:analysis; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000032:analysis / Q000097:blood
D000199:Actins; D001053:Apolipoproteins; D001057:Apolipoproteins E; D002791:Cholesterol, Dietary; D008074:Lipoproteins; D012333:RNA, Messenger; D014280:Triglycerides; D003553:Cystine; D002784:Cholesterol; D006903:Hydroxymethylglutaryl CoA Reductases